Skip to main content

$4.40 0.06 (1.38%)

High

$4.46

Low

$4.23

Trades

1,020

Turnover

$2,463,536

Volume

565,229
30 June 2023 at 4:10pm
Register to track MYX and receive email alerts.
Subject
MYX Ann: Initial Director's Interest Notice

MYX Ann: Notification of cessation of securities - MYX

MYX Ann: Non-Executive Director appointment and retirement

MYX Ann: 2022 Full Year Investor Presentation

MYX Ann: 2022 Full Year Media Release

MYX Ann: Appendix 4E and Statutory Accounts

MYX Ann: Mayne Pharma CEO announces plan to retire

MYX Ann: Ceasing to be a substantial holder

MYX Ann: Mayne Pharma announces sale of Metrics Contract Services

MYX Ann: FDA approval of HALOETTE, a generic version of NUVARING

MYX Ann: Change of Director's Interest Notice

MYX Ann: Notification of cessation of securities - MYX

MYX Ann: NEXTSTELLIS nominated for 2022 Prix Galien USA Award

MYX Ann: Update - Notification of buy-back - MYX

MYX Ann: MYX and GoodRx announce NEXTSTELLIS DTC campaign

MYX Ann: NEXTSTELLIS oral contraceptive now available in Australia

MYX Ann: Mayne Pharma appoints new CFO

MYX Ann: Notification of buy-back - MYX

MYX Ann: Change in substantial holding

MYX Ann: Notification of cessation of securities - MYX

MYX Ann: Wilsons investor conference presentation

MYX Ann: Notice under ASX Listing Rule 3.10A

MYX Ann: Mayne Pharma recipient of $4.8m Federal Government Grant

MYX Ann: Initial Director's Interest Notice

MYX Ann: Non Executive Director Appointment

MYX Ann: Final Director's Interest Notice

MYX Ann: 2022 Half Year Investor Presentation

MYX Ann: 2022 Half Year Media Release

MYX Ann: Half Yearly Report and Accounts

MYX Ann: Ceasing to be a substantial holder

MYX Ann: Notification of cessation of securities - MYX

MYX Ann: Mayne Pharma expands US dermatology portfolio

MYX Ann: Becoming a substantial holder

MYX Ann: Ceasing to be a substantial holder

MYX Ann: Initial Director's Interest Notice

MYX Ann: Non-Executive Director appointment and retirement

MYX Ann: Mayne Pharma adds a generic PROTOPIC to US portfolio

MYX Ann: Change of Director's Interest Notice

MYX Ann: Notification regarding unquoted securities - MYX

MYX Ann: Notification of cessation of securities - MYX

MYX Ann: TGA approval of novel oral contraceptive NEXTSTELLIS

MYX Ann: Results of Meeting

MYX Ann: 2021 Mayne Pharma AGM Speeches

MYX Ann: 2021 AGM Notice of Meeting and Shareholder Pack

MYX Ann: 2021 Corporate Governance Statement and Appendix 4G

MYX Ann: Annual Report to shareholders

MYX Ann: MAYNE PHARMA provides FDA update on generic NUVARING

MYX Ann: Initial Director's Interest Notice

MYX Ann: Final Director's Interest Notice (x2)

MYX Ann: Mayne Pharma appoints new Director

Register to track MYX and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
NEU
PBP
RCE
SPL